

Grand Rounds

Tuesday, October 22, 12:00pm

Smilow Auditorium, 55 Park Street

Join us in person for lunch

[Zoom Access](#)

SLOWING OF TRANSCRIPTION AND EPIGENETIC REWIRING: A NEW PARADIGM TO UNDERSTANDING BIOLOGY OF SPLICING FACTOR MUTATIONS IN CANCER

Prajwal Boddu, MD

Associate Research Scientist

Needs:

Splicing factor mutations are widely prevalent in many cancers;
Alternate paradigms are needed to explain features of splicing factor mutant disease biology;
There is critical unmet need for effective non-transplant therapies in MDS and AML.

Objectives:

1. Recognize the prevalence and impact of splicing factor mutations in cancers, particularly acute myeloid leukemia and myelodysplastic syndromes
2. Examine the need to explore additional mechanisms beyond splicing disruption in these diseases
3. Identify new therapeutic strategies for splicing factor-mutant myelodysplastic syndromes



Prajwal Boddu, MD, is a hematologist with expertise in the diagnosis, treatment, and management of blood disorders and cancers. His goal is to provide patients with the most up-to-date and effective therapies available.

Dr. Boddu was inspired to practice hematology and oncology as he learned about how treatments have the potential to relieve the suffering some patients endure and significantly enhance their outcomes.

In addition to caring for patients, Dr. Boddu is passionate about driving meaningful change through research. He has been involved in outcomes research focused on identifying the most effective treatment strategies for patients with myeloid malignancies. More recently, Dr. Boddu has directed his focus to basic research into the development of novel therapies for patients with splicing factor mutant myelodysplastic syndromes.



Continuing Medical Education
Yale CME

